Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ARDMQ
Aradigm
$0.05
$0.05
$0.02
$0.20
$764KN/A21,923 shsN/A
Hypha Labs, Inc. stock logo
DIGP
Hypha Labs
$0.03
$0.03
$0.01
$0.07
$3.20M0.4399,466 shsN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
$0.00
$0.00
$0.00
$710K-0.21127,366 shsN/A
PTEIQ
PolarityTE
$0.15
$0.05
$0.09
$1.24M0.9227,292 shs313 shs
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ARDMQ
Aradigm
0.00%0.00%0.00%0.00%0.00%
Hypha Labs, Inc. stock logo
DIGP
Hypha Labs
0.00%-0.36%-3.88%-30.25%+3.72%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00%0.00%0.00%-50.00%0.00%
PTEIQ
PolarityTE
0.00%0.00%0.00%+13.33%+70.17%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ARDMQ
Aradigm
N/AN/AN/AN/AN/AN/AN/AN/A
Hypha Labs, Inc. stock logo
DIGP
Hypha Labs
N/AN/AN/AN/AN/AN/AN/AN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
PTEIQ
PolarityTE
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ARDMQ
Aradigm
0.00
N/AN/AN/A
Hypha Labs, Inc. stock logo
DIGP
Hypha Labs
0.00
N/AN/AN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00
N/AN/AN/A
PTEIQ
PolarityTE
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ARDMQ
Aradigm
N/AN/AN/AN/AN/AN/A
Hypha Labs, Inc. stock logo
DIGP
Hypha Labs
$2.70M1.19N/AN/A($0.03) per share-0.93
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/AN/A
PTEIQ
PolarityTE
$810K0.00N/AN/A$2.30 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ARDMQ
Aradigm
N/AN/A0.00N/AN/AN/AN/AN/A
Hypha Labs, Inc. stock logo
DIGP
Hypha Labs
$250KN/A0.00N/AN/AN/A-35.56%N/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/A0.00N/AN/AN/AN/AN/AN/A
PTEIQ
PolarityTE
-$7.83M-$3.28N/AN/AN/AN/A-106.08%-76.91%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ARDMQ
Aradigm
N/AN/AN/AN/AN/A
Hypha Labs, Inc. stock logo
DIGP
Hypha Labs
N/AN/AN/AN/AN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/A
PTEIQ
PolarityTE
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ARDMQ
Aradigm
N/AN/AN/A
Hypha Labs, Inc. stock logo
DIGP
Hypha Labs
N/A
0.91
0.91
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/A
PTEIQ
PolarityTE
N/A
4.11
4.11

Institutional Ownership

CompanyInstitutional Ownership
ARDMQ
Aradigm
N/A
Hypha Labs, Inc. stock logo
DIGP
Hypha Labs
N/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/A
PTEIQ
PolarityTE
11.75%

Insider Ownership

CompanyInsider Ownership
ARDMQ
Aradigm
4.50%
Hypha Labs, Inc. stock logo
DIGP
Hypha Labs
10.80%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
61.50%
PTEIQ
PolarityTE
5.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
ARDMQ
Aradigm
2315.28 millionN/ANot Optionable
Hypha Labs, Inc. stock logo
DIGP
Hypha Labs
20114.71 million102.32 millionNot Optionable
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
47.10 billion2.73 billionNot Optionable
PTEIQ
PolarityTE
607.32 million6.99 millionNot Optionable

Recent News About These Companies

No headlines for this company have been tracked by MarketBeat.com

Aradigm OTCMKTS:ARDMQ

$0.05 0.00 (0.00%)
As of 06/30/2020

Aradigm Corp. is a leading developer of advanced pulmonary drug delivery systems for the treatment of systemic conditions as well as lung diseases. Their hand-held AERx platform is being designed for the rapid and reproducible delivery of a wide range of pharmaceutical drugs and biotech compounds via the lung.

Hypha Labs stock logo

Hypha Labs OTCMKTS:DIGP

$0.03 0.00 (0.00%)
As of 05/28/2025

Hypha Labs, Inc., cultivates, produces, and sells psychedelic and functional mushroom in the United States. It has developed technology that quickly cultivates the mycelium root structures of psilocybin mushrooms and other functional mushroom's mycelium into a natural product. The company was incorporated in 2010 and is headquartered in Las Vegas, Nevada.

Nutra Pharma stock logo

Nutra Pharma OTCMKTS:NPHC

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, and overthecounter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and antiinflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.

PolarityTE NASDAQ:PTEIQ

PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.